168 phenotypes from multigenic genotypes

Allelic Composition Genetic Background	Annotated Term	Reference
Acacbtm1.2Lowl/Acacbtm1.2Lowl Lepob/Lepob involves: 129S6/SvEvTac * FVB/N	increased body weight	J:159285
Adigtm1.1(KOMP)Vlcg/Adigtm1.1(KOMP)Vlcg Lepob/Lepob B6.Cg-Adigtm1.1(KOMP)Vlcg Lepob	decreased body fat mass	J:304292
	decreased body weight	J:304292
	impaired glucose tolerance	J:304292
Adipoqtm1Ish/Adipoqtm1Ish Lepob/Lepob involves: 129S7/SvEvBrd * C57BL/6J	normal cardiovascular system phenotype	J:199264
	decreased carbon dioxide production	J:199264
	decreased energy expenditure	J:199264
	decreased oxygen consumption	J:199264
	impaired glucose tolerance	J:199264
	increased body weight	J:199264
	increased bone mass	J:199264
	increased circulating glucose level	J:199264
	increased susceptibility to weight gain	J:199264
	increased total fat pad weight	J:199264
	increased trabecular bone thickness	J:199264
	increased urine adrenaline level	J:199264
Adipoqtm1Pesch/Adipoqtm1Pesch Lepob/Lepob involves: 129S7/SvEvBrd * C57BL/6J	impaired glucose tolerance	J:107486
Adrb2tm1Kry/Adrb2+ Lepob/Lep+ Tg(Col1a1-cre)1Kry/0 involves: C57BL/6 * C57BL/10J * FVB	decreased circulating glucose level	J:145998
	increased circulating insulin level	J:145998
Ago2tm1.1Tara/Ago2tm1.1Tara Lepob/Lepob Tg(Ins2-cre)23Herr/0 involves: 129P2/OlaHsd * C57BL/6J * CBA/J	decreased circulating glucose level	J:210552
	decreased circulating insulin level	J:210552
	normal endocrine/exocrine gland phenotype	J:210552
	improved glucose tolerance	J:210552
	increased circulating insulin level	J:210552
	increased pancreatic beta cell mass	J:210552
	increased pancreatic beta cell number	J:210552
Agrptm2(HBEGF)Rpa/Agrp+ Lepob/Lepob involves: 129S4/SvJaeSor * C57BL/6	abnormal eating behavior	J:181947
	decreased body temperature	J:181947
	decreased body weight	J:181947
	decreased neuron number	J:181947
	enhanced fertility	J:181947
	improved glucose tolerance	J:181947
	increased susceptibility to induced morbidity/mortality	J:181947
	weight loss	J:181947
Akt2tm1.1Mbb/Akt2+ Lepob/Lepob B6.Cg-Lepob Akt2tm1.1Mbb	decreased body weight	J:155432
	decreased liver triglyceride level	J:155432
	decreased liver weight	J:155432
Akt2tm1.1Mbb/Akt2tm1.1Mbb Lepob/Lepob B6.Cg-Lepob Akt2tm1.1Mbb	abnormal lipid homeostasis	J:155432
	decreased body weight	J:155432
	decreased circulating cholesterol level	J:155432
	decreased liver triglyceride level	J:155432
	decreased liver weight	J:155432
	increased circulating glucose level	J:155432
	increased circulating insulin level	J:155432
Akt2tm1.2Mbb/Akt2tm1.2Mbb Lepob/Lepob Tg(Alb1-cre)1Khk/0 involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * SJL	abnormal lipid homeostasis	J:155432
	decreased body weight	J:155432
	decreased liver triglyceride level	J:155432
	decreased liver weight	J:155432
	increased circulating glucose level	J:155432
Apobtm2Sgy/Apobtm2Sgy Apoetm1Unc/Apoetm1Unc Lepob/Lepob involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6	abnormal circulating cholesterol level	J:133453
	atherosclerotic lesions	J:133453
	decreased circulating HDL cholesterol level	J:133453
	hyperglycemia	J:133453
	hypertension	J:133453
	impaired glucose tolerance	J:133453
	increased circulating cholesterol level	J:133453
	increased circulating free fatty acids level	J:133453
	increased circulating insulin level	J:133453
	increased circulating triglyceride level	J:133453
	increased circulating VLDL cholesterol level	J:133453
	obese	J:133453
Apobtm2Sgy/Apobtm2Sgy Ldlrtm1Her/Ldlrtm1Her Lepob/Lepob involves: 129S7/SvEvBrd * C57BL/6	abnormal circulating cholesterol level	J:133453
	atherosclerotic lesions	J:133453
	decreased circulating HDL cholesterol level	J:133453
	hypertension	J:133453
	increased circulating cholesterol level	J:133453
	increased circulating free fatty acids level	J:133453
	increased circulating insulin level	J:133453
	increased circulating LDL cholesterol level	J:133453
	increased circulating triglyceride level	J:133453
	obese	J:133453
Bglap/Bglap2tm1Kry/Bglap/Bglap2tm1Kry Lepob/Lepob involves: 129S7/SvEvBrd * C57BL/10J	normal endocrine/exocrine gland phenotype	J:145998
	normal homeostasis/metabolism phenotype	J:145998
Bglap/Bglap2tm1Kry/Bglap/Bglap2tm1Kry Lepob/Lepob involves: 129S7/SvEvBrd * C57BL/10J	normal endocrine/exocrine gland phenotype	J:145998
	normal homeostasis/metabolism phenotype	J:145998
Bsxtm1Tre/Bsxtm1Tre Lepob/Lepob B6.Cg-Lepob Bsxtm1Tre	abnormal food intake	J:122746
	decreased core body temperature	J:122746
	decreased locomotor activity	J:122746
	hyperglycemia	J:122746
	increased circulating insulin level	J:122746
	increased lean body mass	J:122746
	polyphagia	J:122746
	reduced female fertility	J:122746
C3tm1Hrc/C3tm1Hrc Lepob/Lepob involves: 129 * C57BL/6	abnormal energy expenditure	J:80546
	abnormal glucose homeostasis	J:80546
	abnormal lipid homeostasis	J:80546
	abnormal oxygen consumption	J:80546
	decreased body weight	J:80546
	decreased circulating insulin level	J:80546
	increased circulating free fatty acids level	J:80546
	increased triglyceride level	J:80546
	polyphagia	J:80546
Ccar2tm1Dac/Ccar2tm1Dac Lepob/Lepob involves: 129 * C57BL/6J	decreased lean body mass	J:228688
	impaired glucose tolerance	J:228688
	increased body weight	J:228688
	increased total body fat amount	J:228688
Cebpatm1Gonz/Cebpatm1Gonz Lepob/Lepob Tg(Alb1-cre)1Dlr/0 involves: 129X1/SvJ * C57BL/6J * FVB/N	abnormal fat cell morphology	J:93579
	abnormal lipid homeostasis	J:93579
	decreased circulating cholesterol level	J:93579
	decreased circulating HDL cholesterol level	J:93579
	decreased circulating insulin level	J:93579
	decreased circulating LDL cholesterol level	J:93579
	decreased liver cholesterol level	J:93579
	decreased liver triglyceride level	J:93579
	decreased susceptibility to diet-induced hepatic steatosis	J:93579
	decreased susceptibility to diet-induced obesity	J:93579
	impaired glucose tolerance	J:93579
	increased circulating free fatty acids level	J:93579
	increased circulating glucose level	J:93579
	increased circulating VLDL cholesterol level	J:93579
	increased liver glycogen level	J:93579
	insulin resistance	J:93579
Cidectm1Pli/Cidectm1Pli Lepob/Lepob involves: C57BL/10J	abnormal adipose tissue amount	J:140122
	abnormal body weight	J:140122
	abnormal gonadal fat pad morphology	J:140122
	decreased circulating free fatty acids level	J:140122
	decreased circulating triglyceride level	J:140122
	improved glucose tolerance	J:140122
	increased insulin sensitivity	J:140122
Clockm1Jt/Clockm1Jt Lepob/Lepob involves: BALB/c * C57BL/6 * C57BL/6J * Jcl:ICR	decreased circulating glucose level	J:135847
	decreased circulating insulin level	J:135847
	increased body weight	J:135847
	increased circulating cholesterol level	J:135847
	increased circulating free fatty acids level	J:135847
	increased circulating glucose level	J:135847
	increased circulating insulin level	J:135847
	increased circulating triglyceride level	J:135847
	increased fat cell size	J:135847
Cnot3tm1.1Tya/Cnot3+ Lepob/Lepob involves: 129P2/OlaHsd * C57BL/6J	normal behavior/neurological phenotype	J:180033
	decreased body weight	J:180033
	decreased respiratory quotient	J:180033
	improved glucose tolerance	J:180033
	increased insulin sensitivity	J:180033
	increased oxygen consumption	J:180033
Dbmc1BTBR/Dbmc1BTBR Lepob/Lepob involves: BTBR * C57BL/6J	abnormal enzyme/coenzyme level	J:119260
Dbmc1BTBR/Dbmc1C57BL/6J Lepob/Lepob involves: BTBR * C57BL/6J	abnormal enzyme/coenzyme level	J:119260
Dbmc2BTBR/Dbmc2BTBR Lepob/Lepob involves: BTBR * C57BL/6J	abnormal enzyme/coenzyme level	J:119260
Dbmc2BTBR/Dbmc2C57BL/6J Lepob/Lepob involves: BTBR * C57BL/6J	abnormal enzyme/coenzyme level	J:119260
Dbmc3BTBR/Dbmc3C57BL/6J Lepob/Lepob involves: BTBR * C57BL/6J	abnormal enzyme/coenzyme level	J:119260
Dbmc3C57BL/6J/Dbmc3C57BL/6J Lepob/Lepob involves: BTBR * C57BL/6J	abnormal enzyme/coenzyme level	J:119260
Dmbx1tm1Sse/Dmbx1tm1Sse Lepob/Lepob involves: ICR	abnormal body weight	J:125193
	abnormal circulating glucose level	J:125193
Fabp4tm1Brsp/Fabp4tm1Brsp Fabp5tm1Hota/Fabp5tm1Hota Lepob/Lepob B6.Cg-Fabp4tm1Brsp Fabp5tm1Hota Lepob	abnormal gluconeogenesis	J:111878
	abnormal glucose homeostasis	J:111878
	abnormal glycogen homeostasis	J:111878
	decreased circulating cholesterol level	J:111878
	decreased circulating glucose level	J:111878
	decreased circulating insulin level	J:111878
	decreased circulating triglyceride level	J:111878
	decreased liver triglyceride level	J:111878
	decreased susceptibility to hepatic steatosis	J:111878
	improved glucose tolerance	J:111878
	increased adipocyte glucose uptake	J:111878
	increased body weight	J:111878
	increased fatty acids level	J:111878
	increased insulin sensitivity	J:111878
	increased muscle cell glucose uptake	J:111878
	increased white adipose tissue amount	J:111878
	small liver	J:111878
Fabp4tm1Brsp/Fabp4tm1Brsp Lepob/Lepob B6.Cg-Fabp4tm1Brsp Lepob	improved glucose tolerance	J:111878
	increased insulin sensitivity	J:111878
Fabp5tm1Hota/Fabp5tm1Hota Lepob/Lepob B6.Cg-Fabp5tm1Hota Lepob	improved glucose tolerance	J:111878
	increased insulin sensitivity	J:111878
Fabp5tm1Hota/Fabp5tm1Hota Lepob/Lepob involves: 129 * C57BL/6J * C57BL/10J * SJL	decreased circulating glucose level	J:81609
	improved glucose tolerance	J:81609
	increased circulating insulin level	J:81609
	increased insulin sensitivity	J:81609
	obese	J:81609
Fitm2tm1.1Dls/Fitm2tm1.1Dls Lepob/Lepob Tg(Fabp4-cre)1Rev/? involves: 129S6/SvEvTac * C57BL/6J	decreased body weight	J:212437
	decreased subcutaneous adipose tissue amount	J:212437
	decreased white adipose tissue amount	J:212437
Ftotm1Urt/Ftotm1Urt Lepob/Lepob involves: 129S1/Sv * 129X1/SvJ * C57BL/6J	abnormal adipose tissue morphology	J:219118
	decreased body length	J:219118
	decreased locomotor activity	J:219118
	enlarged pancreatic islets	J:219118
	hepatic steatosis	J:219118
	increased body weight	J:219118
	increased fat cell size	J:219118
	increased gonadal fat pad weight	J:219118
	increased inguinal fat pad weight	J:219118
	increased interscapular fat pad weight	J:219118
	increased liver weight	J:219118
	increased percent body fat/body weight	J:219118
	insulin resistance	J:219118
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+ Lepob/Lepob Tg(Adipoq-cre)1Evdr/0 involves: 129S4/SvJaeSor * C57BL/6J * FVB/NJ	normal adipose tissue phenotype	J:237232
	hyperglycemia	J:237232
Hmga2tm1Cha/Hmga2+ Lepob/Lepob involves: 129S7/SvEvBrd * C57BL/6J	decreased body size	J:61493
	decreased body weight	J:61493
Hmga2tm1Cha/Hmga2tm1Cha Lepob/Lepob involves: 129S7/SvEvBrd * C57BL/6J	abnormal body weight	J:61493
	abnormal fat pad morphology	J:61493
	decreased body size	J:61493
	decreased inguinal fat pad weight	J:61493
	decreased mesenteric fat pad weight	J:61493
Ildr2Dbsm1-DBA/2J/Ildr2Dbsm1-DBA/2J Lepob/Lepob B6.Cg-Ildr2Dbsm1-DBA/2J Lepob	decreased circulating insulin level	J:138216
	decreased pancreatic beta cell mass	J:138216
	hyperglycemia	J:138216
	impaired glucose tolerance	J:138216
Kittm1Rosay/Kit+ Lepob/Lepob involves: 129S7/SvEvBrd * C57BL/6J	abnormal interstitial cell of Cajal morphology	J:168676
	hyperglycemia	J:168676
	obese	J:168676
	white spotting	J:168676
Ldlrtm1Her/Ldlr+ Lepob/Lepob B6.Cg-Lepob Ldlrtm1Her	increased circulating cholesterol level	J:72027
	increased circulating HDL cholesterol level	J:72027
	increased liver cholesterol level	J:72027
	increased liver triglyceride level	J:72027
Ldlrtm1Her/Ldlrtm1Her Lepob/Lepob B6.Cg-Lepob Ldlrtm1Her	abnormal circulating cholesterol level	J:72027
	atherosclerotic lesions	J:72027
	hyperlipidemia	J:72027
	increased circulating cholesterol level	J:72027
	increased circulating HDL cholesterol level	J:72027
	increased circulating triglyceride level	J:72027
	increased liver cholesterol level	J:72027
	increased liver triglyceride level	J:72027
Lepob/Lep+ Npy4rtm1.1Hhz/Npy4rtm1.1Hhz involves: 129X1/SvJ * C57BL/6	increased body weight	J:76479
	increased white adipose tissue amount	J:76479
Lepob/Lep+ Tg(Apoe-Lepr)1Kry/0 involves: C57BL/6J	increased bone mass	J:88655
	increased total body fat amount	J:88655
Lepob/Lepob Lgals12tm1Ftl/Lgals12+ involves: 129S1/Sv * 129X1/SvJ * C57BL/6	decreased inguinal fat pad weight	J:180097
Lepob/Lepob Lgals12tm1Ftl/Lgals12tm1Ftl involves: 129S1/Sv * 129X1/SvJ * C57BL/6	decreased body weight	J:180097
	decreased gonadal fat pad weight	J:180097
	decreased inguinal fat pad weight	J:180097
Lepob/Lepob Mapk8tm1Wag/Mapk8tm1Wag B6.Cg-Lepob Mapk8tm1Wag	decreased body weight	J:80452
	decreased circulating glucose level	J:80452
	decreased circulating insulin level	J:80452
Lepob/Lepob Mir375tm1Stf/Mir375tm1Stf B6.Cg-Mir375tm1Stf Lepob	abnormal gluconeogenesis	J:147572
	decreased body size	J:147572
	decreased circulating insulin level	J:147572
	decreased pancreatic beta cell mass	J:147572
	decreased pancreatic beta cell number	J:147572
	increased circulating glucose level	J:147572
	increased pancreatic alpha cell number	J:147572
	polydipsia	J:147572
	polyuria	J:147572
Lepob/Lepob Mogat1tm1Far/Mogat1tm1Far involves: 129S4/SvJae	normal homeostasis/metabolism phenotype	J:231617
	increased circulating cholesterol level	J:231617
	increased circulating glucose level	J:231617
	increased circulating insulin level	J:231617
	increased circulating triglyceride level	J:231617
	increased liver triglyceride level	J:231617
	insulin resistance	J:231617
Lepob/Lepob Nfe2l2tm1.1Jgpi/Nfe2l2tm1.1Jgpi Tg(Fabp4-cre)1Rev/0 involves: C57BL/6	abnormal white fat cell morphology	J:208590
	decreased white adipose tissue amount	J:208590
	normal homeostasis/metabolism phenotype	J:208590
	increased circulating glucose level	J:208590
	increased circulating triglyceride level	J:208590
	insulin resistance	J:208590
Lepob/Lepob Nfe2l2tm1Mym/Nfe2l2tm1Mym B6.Cg-Nfe2l2tm1Mym Lepob	abnormal adipose tissue development	J:208590
	abnormal urine color	J:208590
	abnormal white fat cell morphology	J:208590
	decreased body weight	J:208590
	decreased food intake	J:208590
	decreased liver triglyceride level	J:208590
	decreased susceptibility to weight gain	J:208590
	decreased white adipose tissue amount	J:208590
	hepatic steatosis	J:208590
	normal homeostasis/metabolism phenotype	J:208590
	hyperglycemia	J:208590
	increased circulating triglyceride level	J:208590
	insulin resistance	J:208590
	premature death	J:208590
Lepob/Lepob Npy2rtm1.1Hhz/Npy2rtm1.1Hhz involves: 129X1/SvJ * C57BL/6	abnormal adipose tissue amount	J:107169
	abnormal circulating glucose level	J:107169
	abnormal circulating insulin level	J:107169
	abnormal intestine morphology	J:107169
	decreased circulating corticosterone level	J:107169
	decreased circulating testosterone level	J:107169
	decreased epididymal fat pad weight	J:107169
	decreased lean body mass	J:107169
	decreased mesenteric fat pad weight	J:107169
	decreased testis weight	J:107169
	female infertility	J:76479
	increased body weight	J:107169
	increased circulating cholesterol level	J:107169
	increased circulating triglyceride level	J:107169
	increased kidney weight	J:107169
	increased liver weight	J:107169
	increased pancreas weight	J:107169
	male infertility	J:76479, J:107169
	polyphagia	J:107169
Lepob/Lepob Npy2rtm1Pern/Npy2rtm1Pern involves: 129 * BALB/c * C57BL/10J	decreased body weight	J:102651
	decreased circulating free fatty acids level	J:102651
	decreased circulating glucose level	J:102651
	decreased circulating LDL cholesterol level	J:102651
	increased circulating cholesterol level	J:102651
	increased circulating HDL cholesterol level	J:102651
	increased triglyceride level	J:102651
Lepob/Lepob Npy4rtm1.1Hhz/Npy4rtm1.1Hhz involves: 129X1/SvJ * C57BL/6	abnormal adipose tissue amount	J:76479
	abnormal branching of the mammary ductal tree	J:76479
	abnormal circulating testosterone level	J:76479
	abnormal estrous cycle	J:76479
	abnormal ovarian follicle morphology	J:76479
	abnormal vagina orifice morphology	J:76479
	enhanced fertility	J:76479
	normal homeostasis/metabolism phenotype	J:76479
	increased circulating corticosterone level	J:76479
	increased Leydig cell number	J:76479
	increased seminal vesicle weight	J:76479
	increased sperm number	J:76479
	increased susceptibility to weight gain	J:76479
Lepob/Lepob Npy5rtm1Rpa/Npy5rtm1Rpa involves: 129S7/SvEvBrd * C57BL/6	abnormal body weight	J:87803
	increased total fat pad weight	J:87803
	obese	J:87803
	polyphagia	J:87803
Lepob/Lepob Nr1i3tm1Dgen/Nr1i3tm1Dgen B6.Cg-Nr1i3tm1Dgen Lepob	decreased circulating triglyceride level	J:149091
Lepob/Lepob Plin4tm1Vlcg/Plin4tm1Vlcg involves: C57BL/6J	decreased cardiac muscle triglyceride level	J:195987
Lepob/Lepob Pmchtm1.1(HBEGF)Rpa/Pmch+ B6.Cg-Lepob Pmchtm1.1(DTR)Rpa	abnormal postnatal growth	J:181947
	normal behavior/neurological phenotype	J:181947
	decreased body weight	J:181947
	decreased neuron number	J:181947
	female infertility	J:181947
	improved glucose tolerance	J:181947
	reduced male fertility	J:181947
Lepob/Lepob Pmchtm1Emf/Pmchtm1Emf involves: 129S4/SvJae * C57BL/6	abnormal adipose tissue amount	J:85176
	abnormal circulating corticosterone level	J:85176
	abnormal glucose homeostasis	J:85176
	abnormal glucose tolerance	J:85176
	decreased circulating glucose level	J:85176
	decreased locomotor activity	J:85176
	hepatic steatosis	J:85176
	impaired adaptive thermogenesis	J:85176
	increased body weight	J:85176
	increased circulating insulin level	J:85176
	increased food intake	J:85176
	increased oxygen consumption	J:85176
Lepob/Lepob Ppargtm1Avp/Pparg+ involves: 129S2/SvPas * C57BL/6	abnormal glucose homeostasis	J:116568
	abnormal gonadal fat pad morphology	J:116568
	abnormal skeletal muscle morphology	J:116568
	abnormal white adipose tissue amount	J:116568
	decreased body fat mass	J:116568
	decreased body weight	J:116568
	decreased circulating adiponectin level	J:116568
	decreased fat cell size	J:116568
	hepatic steatosis	J:116568
	increased circulating glucose level	J:116568
	increased circulating insulin level	J:116568
	increased circulating triglyceride level	J:116568
	increased liver weight	J:116568
	insulin resistance	J:116568
	polyphagia	J:116568
Lepob/Lepob Ppargtm2Avp/Ppargtm2Avp involves: 129 * C57BL/6	abnormal fat cell morphology	J:121534
	abnormal glucose homeostasis	J:121534
	abnormal insulin secretion	J:121534
	abnormal lipid homeostasis	J:121534
	abnormal liver morphology	J:121534
	abnormal locomotor behavior	J:121534
	abnormal pancreatic islet morphology	J:121534
	abnormal skeletal muscle morphology	J:121534
	decreased circulating adiponectin level	J:121534
	decreased circulating insulin level	J:121534
	decreased liver triglyceride level	J:121534
	decreased locomotor activity	J:121534
	decreased respiratory quotient	J:121534
	decreased triglyceride level	J:121534
	disorganized pancreatic islets	J:121534
	normal endocrine/exocrine gland phenotype	J:121534
	normal growth/size/body region phenotype	J:121534
	hepatic steatosis	J:121534
	hyperglycemia	J:121534
	increased circulating free fatty acids level	J:121534
	increased circulating glucose level	J:121534
	increased circulating insulin level	J:121534
	increased circulating triglyceride level	J:121534
	increased fluid intake	J:121534
	increased percent body fat/body weight	J:121534
	increased urine glucose level	J:121534
	insulin resistance	J:121534
	oxidative stress	J:121534
	polyphagia	J:121534
Lepob/Lepob Ptprvtm1Asmi/Ptprv+ involves: 129P2/OlaHsd * C57BL/10J	increased circulating insulin level	J:145998
Lepob/Lepob Ptprvtm1Asmi/Ptprvtm1Asmi involves: 129P2/OlaHsd * C57BL/10J	decreased circulating glucose level	J:145998
	improved glucose tolerance	J:145998
	increased circulating insulin level	J:145998
Lepob/Lepob Rcan2tm1Ypt/Rcan2tm1Ypt involves: 129 * C57BL/6	decreased body weight	J:169558
	decreased epididymal fat pad weight	J:169558
	decreased liver weight	J:169558
	decreased retroperitoneal fat pad weight	J:169558
Lepob/Lepob Serpine1tm1Mlg/Serpine1tm1Mlg involves: 129S2/SvPas * C57BL/6	abnormal tumor necrosis factor level	J:70695
	impaired glucose tolerance	J:70695
	increased circulating insulin level	J:70695
Lepob/Lepob Sesn2Gt(RRJ141)Byg/Sesn2Gt(RRJ141)Byg involves: 129P2/OlaHsd * C57BL/6	decreased fatty acid beta-oxidation	J:189021
	hepatic steatosis	J:189021
	impaired glucose tolerance	J:189021
	increased circulating glucose level	J:189021
	increased liver triglyceride level	J:189021
	increased urine glucose level	J:189021
	insulin resistance	J:189021
Lepob/Lepob Steap4tm1Dgen/Steap4tm1Dgen involves: 129P2/OlaHsd	hepatic steatosis	J:187736
	increased circulating glucose level	J:187736
	increased percent body fat/body weight	J:187736
Lepob/Lepob Stxbp5lT2dm1/Stxbp5lT2dm1 B6.Cg-Lepob Chr 16BTNTTF	decreased circulating insulin level	J:178002
	increased circulating glucose level	J:178002
Lepob/Lepob Stxbp5lT2dm1/Stxbp5lT2dm1 T2dm2C57BL/6J/T2dm2C57BL/6J involves: BTBR * C57BL/6J	hyperglycemia	J:65486
Lepob/Lepob T2dm2BTBR/T2dm2BTBR involves: BTBR * C57BL/6J	increased circulating insulin level	J:65486
Lepob/Lepob T2dm2BTBR/T2dm2C57BL/6J involves: BTBR * C57BL/6J	increased circulating insulin level	J:65486
Lepob/Lepob Tg(Eno2-Pomc)1Mobb/? involves: C3H * C57BL/6	abnormal body size	J:86303
	abnormal body temperature	J:86303
	abnormal body weight	J:86303
	abnormal fatty acids level	J:86303
	abnormal food intake	J:86303
	abnormal liver size	J:86303
	normal homeostasis/metabolism phenotype	J:86303
Lepob/Lepob Tg(Ins2-Mir184)4Mnpy/0 involves: C57BL/10J	decreased body weight	J:210552
	decreased circulating insulin level	J:210552
	decreased insulin secretion	J:210552
	decreased pancreatic beta cell mass	J:210552
	hyperglycemia	J:210552
	weight loss	J:210552
Lepob/Lepob Tg(Ins2-rtTA)2Efr/0 Tg(tetO-Mir184)#Mnpy/0 involves: C57BL/6 * CBA	decreased circulating insulin level	J:210552
	increased circulating glucose level	J:210552
Lepob/Lepob Tg(Myh6-Med13)1Eno/0 involves: C57BL/6	decreased body weight	J:186193
	improved glucose tolerance	J:186193
Lepob/Lepob Tg(Pmch-ATXN3*)3Rck/0 involves: C57BL/6J * FVB/NJ	abnormal fertility/fecundity	J:104264
	abnormal maternal nurturing	J:104264
	decreased body weight	J:104264
	decreased circulating glucose level	J:104264
	normal liver/biliary system phenotype	J:104264
Lepob/Lepob Tg(tetO-Xbp1_is)#Pesch/0 Tg(Adipoq-rtTA)2Zvw/0 involves: C57BL/6 * C57BL/6N * FVB/N	decreased susceptibility to diet-induced obesity	J:260830
Lepob/Lepob Tnfrsf1atm1Imx/Tnfrsf1atm1Imx Tnfrsf1btm1Imx/Tnfrsf1btm1Imx involves: 129S7/SvEvBrd * C57BL/6	abnormal adipose tissue morphology	J:55722
	abnormal metabolism	J:55722
	decreased circulating insulin level	J:55722
Lepob/Lepob Ucp1tm1Kz/Ucp1tm1Kz involves: 129S2/SvPas * C57BL/6	decreased respiratory quotient	J:129662
	impaired adaptive thermogenesis	J:129662
	increased oxygen consumption	J:129662
	weight loss	J:129662
Npbwr1tm1Rck/Npbwr1tm1Rck Lepob/Lepob involves: 129P/Ola * C57BL/6J	obese	J:94820